Moreover, the Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus–Thrombolysis in Myocardial Infarction 53 (SAVOR-TIMI 53) trial [1,2] showed that DPPIV inhibition reduces albuminuria in T2DM subjects with CKD, suggesting that the DPPIV inhibitors may confer renoprotective effects that extend beyond glycemic control. This evidence concerns the gene DPP4 and diabetes mellitus.